CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

furosemide

Trade name: lasix

Small moleculeapproved

Approved

Jul 1, 1966

Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic. Furosemide is sold under the brand name Lasix among others. — NCATS

Clinical trial activity

258 trials · 264 clinical orgs · 50 marketing orgs

Phase 1
61
Phase 2
85
Phase 3
48
Phase 4
60

Earliest trial started May 1, 1996 (NCT00175227)

Timeline

1960s

  1. Jul 1, 1966

    Earliest FDA Approval

  2. Jul 1, 1966

    Validus Pharmaceuticals — NDA Secondary Org

  3. Jul 1, 1966

    Validus Pharmaceuticals — Marketing Organization

  4. Mar 20, 1968

    Sanofi-Aventis — NDA Secondary Org

1970s

  1. Jan 10, 1979

    International Medication — NDA Secondary Org

1980s

  1. May 19, 1981

    West-Ward Pharmaceutical — NDA Secondary Org

  2. May 19, 1981

    Hikma — Marketing Organization

  3. Aug 27, 1981

    Mylan — NDA Secondary Org

  4. Oct 19, 1981

    Epic Pharma Llc — Marketing Organization

  5. Oct 19, 1981

    Sandoz — NDA Secondary Org

  6. Oct 19, 1981

    Epic Pharma Llc — NDA Secondary Org

  7. May 14, 1982

    Watson Pharmaceuticals — NDA Secondary Org

  8. May 28, 1982

    Hospira — NDA Secondary Org

  9. Jul 27, 1982

    DAVA Pharmaceuticals — NDA Secondary Org

  10. Jul 27, 1982

    Strides Pharma Science — Marketing Organization

  11. Jul 27, 1982

    Strides Pharma Science — NDA Secondary Org

  12. Oct 6, 1983

    Sun Pharmaceuticals — NDA Secondary Org

  13. Nov 10, 1983

    Hikma — NDA Secondary Org

  14. Nov 30, 1983

    Heritage Pharma — NDA Secondary Org

  15. Nov 30, 1983

    Lutipold — NDA Secondary Org

  16. Nov 30, 1983

    Sankyo — Marketing Organization

  17. Nov 30, 1983

    Heritage Pharma — Marketing Organization

  18. Nov 30, 1983

    Chartwell Pharmaceuticals — Marketing Organization

  19. Nov 30, 1983

    Sankyo — NDA Secondary Org

  20. Nov 30, 1983

    Chartwell Pharmaceuticals — NDA Secondary Org

  21. May 22, 1984

    Fresenius — NDA Secondary Org

  22. Sep 26, 1985

    Sun Pharmaceuticals — Marketing Organization

  23. Nov 22, 1985

    Teva — Marketing Organization

  24. Feb 26, 1986

    Watson Pharmaceuticals — Marketing Organization

  25. Oct 29, 1986

    Mylan — Marketing Organization

  26. Dec 15, 1986

    Accord Research — Marketing Organization

  27. Jul 8, 1987

    Hospira — Marketing Organization

  28. Oct 1, 1987

    Xttrium Laboratories — Marketing Organization

  29. Feb 9, 1988

    Ani Pharmaceuticals — Marketing Organization

  30. May 17, 1989

    Superpharm — NDA Secondary Org

2000s

  1. Jan 1, 2003

    Sankyo — Earliest Phase 3 Sponsor(trial)

  2. Mar 26, 2004

    Prinston Inc — Marketing Organization

  3. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  4. Nov 9, 2005

    Leading Pharma Llc — Marketing Organization

  5. Sep 18, 2006

    IPCA Laboratories Ltd. — Marketing Organization

  6. Mar 22, 2007

    Wockhardt — Marketing Organization

  7. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 27, 2014

    Baxalta — Marketing Organization

  2. Aug 26, 2014

    Emcure — Marketing Organization

  3. Aug 26, 2014

    Avet Lifesciences — Marketing Organization

  4. Jul 20, 2016

    Amneal Pharmaceuticals — Marketing Organization

  5. May 3, 2019

    Aurobindo Pharma — Marketing Organization

  6. May 3, 2019

    Eugia Pharma — Marketing Organization

2020s

  1. Jul 1, 2020

    Gland Pharma Ltd — Marketing Organization

  2. Jul 1, 2020

    Fosun — Marketing Organization

  3. Dec 18, 2020

    Areva Med LLC — Marketing Organization

  4. Jan 27, 2021

    Athenex, Inc. — Marketing Organization

  5. Jan 27, 2022

    Meitheal — Marketing Organization

  6. Oct 7, 2022

    scPharmaceuticals, Inc. — Marketing Organization

  7. Oct 7, 2022

    scPharmaceuticals, Inc. — NDA Secondary Org

  8. Oct 17, 2022

    Graviti Pharmaceuticals — Marketing Organization

  9. Dec 16, 2022

    Mankind Pharma — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewJul 1, 1966

Chemistry & pharmacology

Loading structure…

SMILES

NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
Mol. weight
330.744 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-chloro-5-(1h-tetrazole-5-yl)-n^4-(2-thenyl)
  • 2-furfurylamino-4-chloro-5-sulfamoylbenzoic acid
  • 2-furfurylamino-4-chloro-5-sulfamoylbenzoic acid
  • 4-chloro-5-sulfamoyl-n-furfuryl-anthranilic acid
  • 4-chloro-5-sulfamoyl-n-furfuryl-anthranilic acid
  • 4-chloro-n-(2-furylmethyl)-5-sulfamoylanthranilic acid
  • 4-chloro-n-(2-furylmethyl)-5-sulfamoylanthranilic acid
  • 4-chloro-n-furfuryl-5-sulfamoylanthranilic acid
  • 4-chloro-n-furfuryl-5-sulfamoylanthranilic acid
  • 5-(4-chloro-5-sulfamyl-2-thienylaminophenyl)tetrazole
  • aluzine 20
  • aluzine 40
  • aluzine 500
  • aquamed
  • azosemid
  • azosemid
  • azosemide
  • azosemide
  • azosemide
  • azosemide
  • azosemide
  • azosemide
  • azosemide
  • azosemide
  • benzenesulfonamide, 2-chloro-5-(1h-tetrazol-5-yl)-4-((2-thienylmethyl)amino)-
  • bm 02.001
  • disal
  • disal
  • diurapid
  • diuresal
  • diuresal
  • dryptal
  • dryptal
  • froop
  • frumax
  • frumil
  • frumil
  • frumil
  • frusemide
  • frusemide
  • frusemide
  • frusemide
  • frusemide
  • frusemide
  • frusemide
  • frusetic
  • frusetic
  • frusid
  • frusid
  • frusol
  • fupiram
  • furosemid
  • furosemid
  • furosemid
  • furosemida
  • furosemida
  • furosemide
  • furosemide
  • furosemide
  • furosemide
  • furosemide
  • furosemide
  • furosemide
  • furosemide
  • furosemide
  • furosemidu
  • furosemidu
  • furosemidum
  • furosemidum
  • hydroled
  • hydroled
  • lasix
  • lasix
  • lasix
  • lasix
  • lasix ret
  • lasix (tn)
  • lasix (tn)
  • lb-502
  • lb-502
  • ple 1053
  • rusyde
  • rusyde
  • tenkofruse

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06941415Phase 3Mar 1, 2026University of Utah
NCT07269496Phase 1Jan 15, 2026BDD Pharma Ltd, SQ Innovation, Inc.
NCT07263035Phase 4Jan 1, 2026Lakeland Regional Medical Center
NCT07018297Phase 3Dec 31, 2025The University of Texas, Dallas
NCT07167862Phase 4Nov 1, 2025University of California, Irvine
NCT07077772N/AOct 31, 2025University of Picardie Jules Verne
NCT07073157Phase 1Jul 15, 2025Hengrui Therapeutics, Inc.
NCT06898515Phase 3Jul 14, 2025Baylor Scott and White, Reprieve Cardiovascular, Inc
NCT06921603N/AJun 29, 2025American Heart Association, University of Pittsburgh
NCT06821594Early Phase 1 (Phase 1)Apr 1, 2025Jinnah Postgraduate Medical Centre
NCT06899061Phase 1Mar 25, 2025AstraZeneca, Parexel
NCT07008365Phase 3Mar 10, 2025Instituto de Investigación Sanitaria Aragón
NCT06407401Phase 3Dec 31, 2024European Organisation for Research and Treatment of Cancer
NCT07307131Phase 2Sep 1, 2024Benha University
NCT06504862Phase 1Aug 19, 2024Boehringer Ingelheim
NCT06786728N/AAug 10, 2024Benha University
NCT06442280Phase 4Jun 30, 2024University of Palermo
NCT06362668N/AMay 17, 2024Reprieve Cardiovascular, Inc
NCT06273397N/AMay 1, 2024Clinica Alemana de Santiago
NCT06326112Phase 2May 1, 2024Canadian Institutes of Health Research (CIHR), Unity Health Toronto
Showing 20 of 258 trials
Page 1 / 13

Organizations

Research & Development (264)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
scPharmaceuticals, Inc.For profit11832014
Boehringer IngelheimFor profit7722014
Cutanea Life Sciences, Inc.For profit6622014
Duke UniversityAcademic/Hospital5432008
Harvard UniversityAcademic/Hospital5232008
National Heart, Lung, and Blood Institute (NHLBI)Government5042008
University of TorontoAcademic/Hospital5442007
University of AlbertaAcademic/Hospital4431996
University of CopenhagenAcademic/Hospital4322015
University of ParisAcademic/Hospital4432007
Yale UniversityAcademic/Hospital4432007
Emory UniversityAcademic/Hospital3232016
Mayo ClinicAcademic/Hospital3322009
National Cancer Institute (NCI)Government3212007
National Institutes of Health (NIH)Government3032003
SQ Innovation, Inc.For profit3322020
Tel Aviv UniversityAcademic/Hospital3312009
University of CincinnatiAcademic/Hospital3322011
University of North Carolina at Chapel HillAcademic/Hospital3322008
University of PalermoAcademic/Hospital3322011
264 organizations
Page 1 / 14

Marketing (66)

OrganizationOrg typeRelationshipDate
AbraxisFor profitNDA2—
Accord ResearchFor profitMKTGDec 15, 1986
American Home ProductsFor profitNDA2—
Amneal PharmaceuticalsFor profitMKTGJul 20, 2016
Ani PharmaceuticalsFor profitSYNFeb 26, 1986
Ani PharmaceuticalsFor profitMKTGFeb 9, 1988
Areva Med LLCFor profitMKTGDec 18, 2020
AstraZenecaFor profitMKTG—
Athenex, Inc.For profitMKTGJan 27, 2021
Aurobindo PharmaFor profitMKTGMay 3, 2019
Avet LifesciencesFor profitMKTGAug 26, 2014
BaxaltaFor profitMKTGJan 27, 2014
Chartwell PharmaceuticalsFor profitMKTGNov 30, 1983
Chartwell PharmaceuticalsFor profitNDA2Nov 30, 1983
DAVA PharmaceuticalsFor profitNDA2Jul 27, 1982
EmcureFor profitMKTGAug 26, 2014
Epic Pharma LlcFor profitMKTGOct 19, 1981
Epic Pharma LlcFor profitNDA2Oct 19, 1981
Eugia PharmaFor profitMKTGMay 3, 2019
FosunFor profitMKTGJul 1, 2020
FreseniusFor profitNDA2May 22, 1984
Gland Pharma LtdFor profitMKTGJul 1, 2020
Graviti PharmaceuticalsFor profitMKTGOct 17, 2022
Heritage PharmaFor profitNDA2Nov 30, 1983
Heritage PharmaFor profitMKTGNov 30, 1983
HikmaFor profitNDA2Nov 10, 1983
HikmaFor profitMKTGMay 19, 1981
HospiraFor profitNDA2May 28, 1982
HospiraFor profitMKTGJul 8, 1987
IPCA Laboratories Ltd.For profitMKTGSep 18, 2006
International MedicationFor profitNDA2Jan 10, 1979
Kala PharmaceuticalsFor profitNDA2—
Leading Pharma LlcFor profitMKTGNov 9, 2005
Leading Pharma LlcFor profitSYNNov 9, 2005
LutipoldFor profitNDA2Nov 30, 1983
Mankind PharmaFor profitMKTGDec 16, 2022
Marsam PharmaceuticalsFor profitMKTG—
MeithealFor profitMKTGJan 27, 2022
MylanFor profitNDA2Aug 27, 1981
MylanFor profitMKTGOct 29, 1986
Prinston IncFor profitMKTGMar 26, 2004
SandozFor profitNDA2Oct 19, 1981
SankyoFor profitMKTGNov 30, 1983
SankyoFor profitNDA2Nov 30, 1983
SanofiFor profitNDA—
Sanofi-AventisFor profitNDA2Mar 20, 1968
Smith & NephewFor profitMKTG—
Strides Pharma ScienceFor profitMKTGJul 27, 1982
Strides Pharma ScienceFor profitNDA2Jul 27, 1982
Sun PharmaceuticalsFor profitNDA2Oct 6, 1983
Sun PharmaceuticalsFor profitSYNSep 26, 1985
Sun PharmaceuticalsFor profitMKTGSep 26, 1985
SuperpharmFor profitNDA2May 17, 1989
Teligent PharmaceuticalsFor profitMKTG—
TevaFor profitMKTGNov 22, 1985
Validus PharmaceuticalsFor profitNDA2Jul 1, 1966
Validus PharmaceuticalsFor profitMKTGJul 1, 1966
Warner ChilcottFor profitNDA2—
Watson PharmaceuticalsFor profitNDA2May 14, 1982
Watson PharmaceuticalsFor profitMKTGFeb 26, 1986
West-Ward PharmaceuticalFor profitNDA2May 19, 1981
WockhardtFor profitMKTGMar 22, 2007
WockhardtFor profitSYNOct 1, 1987
Xttrium LaboratoriesFor profitMKTGOct 1, 1987
scPharmaceuticals, Inc.For profitMKTGOct 7, 2022
scPharmaceuticals, Inc.For profitNDA2Oct 7, 2022